WASHINGTON -- The Food and Drug Administration on Friday approved Teva Pharmaceutical's drug Synribo to treat patients with a type of blood and bone marrow cancer.
The agency cleared the injectable drug for patients with chronic myelogenous leukemia which has spread despite treatment with two other cancer drugs.
An estimated 5,430 people will be diagnosed with the cancer this year, according to the National Institutes of Health.
The drug works by blocking proteins that help cancer cells grow.
Teva Pharmaceutical Industries Ltd. is headquartered in Israel, with U.S. offices in Frazer, Pa.